Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533098
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
A Study of Nipocalimab or Intravenous Immunoglobulin IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia FNAIT
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Multicenter Open-Label Randomized Study of Nipocalimab or Intravenous Immunoglobulin IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia FNAIT
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FREESIA-3
Brief Summary:
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None